Author

Jose Sandoval

Institution: University Hospital of Geneva

Observed institution: University Hospital of Geneva

ORCID: 0000-0002-6256-7083

Observed ORCID: 0000-0002-6256-7083

OpenAlex ID: A5137217892

Navigating first- and second-line treatment options in hormone receptor-positive HER2-negative advanced breast cancer

2026 · Jose Sandoval, Patrick Neven, et al. · The Oncologist

NoLEEta: No chemotherapy in intermediate-risk HR+ HER2− early breast cancer treated with ribociclib in the adjuvant setting—A non-inferiority phase III trial.

2026 · Francois Clement Bidard, Thomas Bachelot, et al. · Journal of Clinical Oncology

Works count: 2

Citation count:

H-index:

I10-index: